13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Research progress on the PEGylation of therapeutic proteins and peptides (TPPs)

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          With the rapid advancement of genetic and protein engineering, proteins and peptides have emerged as promising drug molecules for therapeutic applications. Consequently, there has been a growing interest in the field of chemical modification technology to address challenges associated with their clinical use, including rapid clearance from circulation, immunogenicity, physical and chemical instabilities (such as aggregation, adsorption, deamination, clipping, oxidation, etc.), and enzymatic degradation. Polyethylene glycol (PEG) modification offers an effective solution to these issues due to its favorable properties. This review presents recent progress in the development and application of PEGylated therapeutic proteins and peptides (TPPs). For this purpose, firstly, the physical and chemical properties as well as classification of PEG and its derivatives are described. Subsequently, a detailed summary is provided on the main sites of PEGylated TPPs and the factors that influence their PEGylation. Furthermore, notable instances of PEG-modified TPPs (including antimicrobial peptides (AMPs), interferon, asparaginase and antibodies) are highlighted. Finally, we propose the chemical modification of TPPs with PEG, followed by an analysis of the current development status and future prospects of PEGylated TPPs. This work provides a comprehensive literature review in this promising field while facilitating researchers in utilizing PEG polymers to modify TPPs for disease treatment.

          Related collections

          Most cited references198

          • Record: found
          • Abstract: found
          • Article: not found

          Antimicrobial peptides of multicellular organisms.

          Multicellular organisms live, by and large, harmoniously with microbes. The cornea of the eye of an animal is almost always free of signs of infection. The insect flourishes without lymphocytes or antibodies. A plant seed germinates successfully in the midst of soil microbes. How is this accomplished? Both animals and plants possess potent, broad-spectrum antimicrobial peptides, which they use to fend off a wide range of microbes, including bacteria, fungi, viruses and protozoa. What sorts of molecules are they? How are they employed by animals in their defence? As our need for new antibiotics becomes more pressing, could we design anti-infective drugs based on the design principles these molecules teach us?
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies.

            Short cationic amphiphilic peptides with antimicrobial and/or immunomodulatory activities are present in virtually every life form, as an important component of (innate) immune defenses. These host-defense peptides provide a template for two separate classes of antimicrobial drugs. Direct-acting antimicrobial host-defense peptides can be rapid-acting and potent, and possess an unusually broad spectrum of activity; consequently, they have prospects as new antibiotics, although clinical trials to date have shown efficacy only as topical agents. But for these compounds to fulfill their therapeutic promise and overcome clinical setbacks, further work is needed to understand their mechanisms of action and reduce the potential for unwanted toxicity, to make them more resistant to protease degradation and improve serum half-life, as well as to devise means of manufacturing them on a large scale in a consistent and cost-effective manner. In contrast, the role of cationic host-defense peptides in modulating the innate immune response and boosting infection-resolving immunity while dampening potentially harmful pro-inflammatory (septic) responses gives these peptides the potential to become an entirely new therapeutic approach against bacterial infections.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Antimicrobial Peptides: An Emerging Category of Therapeutic Agents

              Antimicrobial peptides (AMPs), also known as host defense peptides, are short and generally positively charged peptides found in a wide variety of life forms from microorganisms to humans. Most AMPs have the ability to kill microbial pathogens directly, whereas others act indirectly by modulating the host defense systems. Against a background of rapidly increasing resistance development to conventional antibiotics all over the world, efforts to bring AMPs into clinical use are accelerating. Several AMPs are currently being evaluated in clinical trials as novel anti-infectives, but also as new pharmacological agents to modulate the immune response, promote wound healing, and prevent post-surgical adhesions. In this review, we provide an overview of the biological role, classification, and mode of action of AMPs, discuss the opportunities and challenges to develop these peptides for clinical applications, and review the innovative formulation strategies for application of AMPs.
                Bookmark

                Author and article information

                Contributors
                Role: Role: Role:
                Role: Role: Role: Role:
                Role: Role: Role:
                Role: Role: Role:
                Role:
                URI : https://loop.frontiersin.org/people/2293952/overviewRole: Role: Role:
                Role: Role:
                Role: Role:
                URI : https://loop.frontiersin.org/people/778550/overviewRole: Role: Role: Role: Role: Role:
                Journal
                Front Pharmacol
                Front Pharmacol
                Front. Pharmacol.
                Frontiers in Pharmacology
                Frontiers Media S.A.
                1663-9812
                08 March 2024
                2024
                : 15
                : 1353626
                Affiliations
                [1] 1 Institute of Feed Research , Chinese Academy of Agricultural Sciences , Beijing, China
                [2] 2 Key Laboratory of Feed Biotechnology , Ministry of Agriculture and Rural Affairs , Beijing, China
                [3] 3 State Key Laboratory of Pathogen and Biosecurity , Beijing Institute of Biotechnology , Beijing, China
                Author notes

                Edited by: Xavier Vila Farres, Contrafect, United States

                Reviewed by: Rita Vanbever, Université Catholique de Louvain, Belgium

                Ofentse Jacob Pooe, University of KwaZulu-Natal, South Africa

                *Correspondence: Zhenlong Wang, wangzhenlong02@ 123456caas.cn ; Xiumin Wang, wangxiumin@ 123456caas.cn
                [ † ]

                These authors have contributed equally to this work

                Article
                1353626
                10.3389/fphar.2024.1353626
                10960368
                38523641
                dbfbcd2d-65b5-4327-8fb3-d29653fc2462
                Copyright © 2024 Li, Li, Tian, An, Wang, Han, Tao, Wang and Wang.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 11 December 2023
                : 22 February 2024
                Funding
                The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Natural Science Foundation of China (Grant No. 32072770).
                Categories
                Pharmacology
                Review
                Custom metadata
                Pharmacology of Infectious Diseases

                Pharmacology & Pharmaceutical medicine
                pegylation,therapeutic protein,antimicrobial peptides,antibodies,modification

                Comments

                Comment on this article